| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
|---|---|---|---|---|---|---|
| 2019 | Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations | SHENG-KAI LIANG ; Ko J.-C.; Yang J.C.-H.; Shih J.-Y. | Lung Cancer | 7 | 6 | |
| 2019 | Albers-Sch?nberg disease | Keng L.-T.; SHENG-KAI LIANG | Korean Journal of Internal Medicine | 0 | 0 | |
| 2014 | Bacteraemia caused by Mycobacterium abscessus subsp. abscessus and M. abscessus subsp. bolletii: Clinical features and susceptibilities of the isolates | Lee M.-R.; Ko J.-C.; SHENG-KAI LIANG ; Lee S.-W.; Yen D.H.-T.; Hsueh P.-R. | International Journal of Antimicrobial Agents | 11 | 10 | |
| 2015 | Clinical characteristics of bacteraemia caused by Lactobacillus spp. and antimicrobial susceptibilities of the isolates at a medical centre in Taiwan, 2000-2014 | Lee M.-R.; Tsai C.-J.; SHENG-KAI LIANG ; Lin C.-K.; Huang Y.-T.; Hsueh P.-R. | International Journal of Antimicrobial Agents | 15 | 15 | |
| 2013 | Evaluating pleural ADA, ADA2, IFN-γ and IGRA for diagnosing tuberculous pleurisy | Keng L.-T.; Shu C.-C.; Chen J.Y.P.; SHENG-KAI LIANG ; Lin C.-K.; Chang L.-Y.; Chang C.-H.; Wang J.-Y.; Yu C.-J.; Lee L.-N. | Journal of Infection | 38 | ||
| 2019 | Foxm1 Transcription Factor Regulates Lung Adenocarcinoma Development | SHENG-KAI LIANG ; Chao S.-Y.; Li C.-C.; Ip K.-U.; Lin Y.-K.; Hsu C.-C.; Hsu P.-C.; Wang I.-C. | IOP Conference Series: Earth and Environmental Science | 0 | ||
| 2012 | Otitis media and otomastoiditis caused by Mycobacterium massiliense (Mycobacterium abscessus subsp. bolletii) | Lee M.-R.; Tsai H.-Y.; Cheng A.; Liu C.-Y.; Huang Y.-T.; Liao C.-H.; SHENG-KAI LIANG ; Lee L.-N.; Hsueh P.-R. | Journal of Clinical Microbiology | 15 | 14 | |
| 2012 | Performance assessment of the DR. TBDR/NTM IVD kit for direct detection of Mycobacterium tuberculosis isolates, including rifampin-resistant isolates, and nontuberculous mycobacteria | Lee M.-R.; Cheng A.; Huang Y.-T.; Liu C.-Y.; Chung K.-P.; Wang H.-C.; SHENG-KAI LIANG ; Liao C.-H.; Yu C.-J.; Hsueh P.-R. | Journal of Clinical Microbiology | 14 | 15 | |
| 2020 | Predicting lung cancer occurrence in never-smoking females in Asia: TNSF-SQ, a prediction model | Chien L.-H.; Chen C.-H.; Chen T.-Y.; Chang G.-C.; Tsai Y.-H.; Hsiao C.-F.; Chen K.-Y.; Su W.-C.; Wang W.-C.; Huang M.-S.; Chen Y.-M.; Chen C.-Y.; SHENG-KAI LIANG ; Chen C.-Y.; Wang C.-L.; Lee M.-H.; Chung R.-H.; Tsai F.-Y.; Hu J.-W.; Katki H.A.; Chatterjee N.; Chanock S.J.; Rothman N.; Lan Q.; Yang P.-C.; Chen C.-J.; Chang I.-S.; Hsiung C.A. | Cancer Epidemiology Biomarkers and Prevention | 3 | 3 | |
| 2018 | Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study | SHENG-KAI LIANG ; Lee M.-R.; Liao W.-Y.; Ho C.-C.; Ko J.-C.; Shih J.-Y. | Oncotarget | 0 | ||
| 2020 | Pulmonary granulomas: Give it a whorl | Keng L.-T.; Lo W.-Y.; Huang H.-N.; Ko H.-J.; SHENG-KAI LIANG | Thorax | 0 | ||
| 2020 | Pulmonary granulomas: Give it a whorl | WEI-YUNG LO ; SHENG-KAI LIANG ; LI-TA KENG ; Hsien-Neng Huang , Huan-Jang Ko | Thorax | 0 | ||
| 2017 | Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma | SHENG-KAI LIANG ; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; Ko J.-C.; Shih J.-Y. | Oncotarget | 29 | ||
| 2017 | Significant clinical factors associated with long-term mortality in critical cancer patients requiring prolonged mechanical ventilation | Keng L.-T.; Chung K.-P.; Lin S.-Y.; SHENG-KAI LIANG ; Cheng J.-C.; Chen I.-C.; Chen Y.-F.; Chang H.-T.; Hsu C.-L.; Jerng J.-S.; Wang H.-C.; Kuo P.-H.; Wu H.-D.; Shih J.-Y.; Yu C.-J. | Scientific Reports | 3 | 3 | |
| 2016 | Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells | Pan C.-H.; Chang Y.-F.; Lee M.-S.; Wen B.-C.; Ko J.-C.; SHENG-KAI LIANG ; Liang M.-C. | BMC Cancer | 17 | 15 |
